Related Experiment Video
Updated: Sep 6, 2025

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
Published on: February 10, 2023
Prophylaxis of Venous Thromboembolism in Children: A Systematic Review
Lotte Hejberg Pedersen1, Gitte Bonde Villadsen1, Maja Hellfritzsch2
1Faculty of Health, Aarhus University, Aarhus, Denmark.
Insights
Pharmacological thromboprophylaxis for pediatric venous thromboembolism (VTE) is under-researched. Evidence suggests it benefits critically ill children with multiple risk factors, without increasing bleeding risk.
Area of Science:
- Pediatric Hematology
- Critical Care Medicine
- Pharmacology
Background:
- Pediatric venous thromboembolism (VTE) is rare but serious.
- Current VTE prophylaxis guidelines for children lack robust evidence, relying on adult data and expert opinion.
Purpose of the Study:
- To systematically review evidence on the benefits of pharmacological thromboprophylaxis (low molecular weight heparin or unfractionated heparin) in children (≤18 years).
- To identify specific pediatric populations that may benefit from thromboprophylaxis.
Main Methods:
- Systematic review of studies published up to October 3, 2021, searching MEDLINE and Embase.
- Included studies compared pharmacological thromboprophylaxis with no prophylaxis in children with radiologically verified VTE.
- Data from 10 studies involving 976 children were analyzed across three population categories: intensive care unit (ICU), fracture/surgery, and systemic disease.
Main Results:
- Reduced VTE incidence with thromboprophylaxis was observed in specific ICU populations (central venous catheter, mechanical ventilation; trauma with high risk) and children with acute lymphoblastic leukemia (ALL) on L-asparaginase/steroids with a central venous catheter.
- No significant increase in bleeding risk was associated with pharmacological thromboprophylaxis.
- VTE incidence was lower with prophylaxis in ICU patients with central venous catheter and mechanical ventilation (7/27 vs 13/24), ICU trauma patients (0/21 vs 13/96), and ALL patients (0/82 vs 8/121).
Conclusions:
- Pharmacological thromboprophylaxis in children is sparsely investigated.
- Evidence suggests thromboprophylaxis may benefit pediatric patients with multiple VTE risk factors, particularly in critical care settings.
- Further research is needed to establish clear guidelines for pediatric VTE prophylaxis.
Abstract:
Venous thromboembolism (VTE) in children is a rare but serious event. Current guidance on pharmacological thromboprophylaxis in children is mostly based on adult studies and expert opinions. The aim of this systematic review was to examine under which conditions children (age ≤ 18 years) would benefit from pharmacological thromboprophylaxis with low molecular weight heparin or unfractionated heparin. Eligible studies included children, who did not receive pharmacological thromboprophylaxis as comparator, and VTE events were radiologically verified. MEDLINE and Embase were searched up to October 3, 2021. Ten studies were included presenting data for 976 children receiving pharmacological thromboprophylaxis. We divided the studies into three categories based on the population studied: children in the intensive care unit (n = 2), children with fractures and/or undergoing surgery (n = 5), and children with systemic disease (n = 3). A lower incidence of VTE was found when pharmacological thromboprophylaxis was used compared with no prophylaxis in children in intensive care unit with central venous catheter and mechanical ventilation (7/27 vs. 13/24), children in the intensive care unit admitted after trauma with a very high risk of VTE based on several risk factors (0/21 vs. 13/96), and children with acute lymphoblastic leukemia treated with L-asparaginase concomitant with steroid and presence of central venous catheter (0/82 vs. 8/121). Pharmacological thromboprophylaxis was not associated with an increased bleeding risk. In conclusion, pharmacological thromboprophylaxis in children is sparsely investigated. Only children with several risk factors for VTE are likely to benefit from pharmacological thromboprophylaxis.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

